DOI:
10.1055/s-00030576
Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics
LinksClose Window
References
Drake MJ, Chapple C, Esen AA , et al; BESIDE study investigators.
Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3b study (BESIDE).
Eur Urol 2016;
70 (1) 136-145
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.